Flibanserin ZPHC — 50 mg × 100 Tablets

Flibanserin ZPHC Overview

Flibanserin ZPHC — 50 mg × 100 tablets is a product labeled as containing flibanserin, a prescription medicine used for a specific form of hypoactive sexual desire disorder (HSDD). For U.S. consumers and healthcare professionals, understanding the active ingredient, approved indication, dosage, interactions, and safety warnings is essential before considering treatment.

Flibanserin is the active ingredient in the FDA-approved medicine Addyi. Under the current FDA labeling, flibanserin is indicated for women younger than 65 years with acquired, generalized hypoactive sexual desire disorder (HSDD) when the condition causes significant distress or interpersonal difficulty and is not attributable to another medical or psychiatric condition, relationship problems, or medications or other drugs. It is not indicated to enhance sexual performance.

Because the requested product is listed as 50 mg × 100 tablets, consumers should not assume that this presentation corresponds to the FDA-approved U.S. strength. Current FDA prescribing information identifies 100 mg tablets as the approved dosage form and recommends 100 mg once daily at bedtime under the labeled conditions of use.

What Is Flibanserin?

Flibanserin is a centrally acting prescription medicine developed for the treatment of certain cases of acquired, generalized HSDD. Unlike medicines intended to enhance sexual performance, its FDA-approved indication concerns persistent low sexual desire associated with clinically significant distress.

The distinction is important. FDA labeling specifically states that flibanserin is not indicated as a general sexual-performance enhancer. Appropriate diagnosis is therefore an important part of determining whether treatment is suitable.

For consumers researching ZPHC Flibanserin, the most important considerations are not simply tablet quantity or labeled strength. They include whether the medication is appropriate for the individual, whether the supplied strength matches the prescribed treatment, potential drug interactions, alcohol-related risks, and other contraindications.

Key Product Information

• Product: Flibanserin ZPHC
• Listed presentation: 50 mg × 100 tablets
• Active ingredient: Flibanserin
• Medication category: Prescription medicine
• FDA-approved flibanserin tablet strength: 100 mg
• FDA-labeled administration: Once daily at bedtime
• U.S. labeled indication: Acquired, generalized HSDD in women younger than 65 years who meet the specified diagnostic criteria
• Not indicated for: Sexual-performance enhancement
• Important considerations: Alcohol, CYP3A4 inhibitors, liver impairment, CNS depression, hypotension, and syncope

Understanding the FDA-Approved Use

Flibanserin is intended for a narrowly defined medical condition rather than general changes in sexual activity or performance.

The FDA describes acquired HSDD as low sexual desire that developed after a period without the problem. Generalized HSDD means that the low desire occurs regardless of the type of stimulation, situation, or partner. The condition must also produce marked distress or interpersonal difficulty and cannot be explained by another medical or psychiatric condition, relationship problems, or the effects of another medication or drug.

This makes professional assessment particularly important. Low sexual desire can have many possible causes, and treatment depends on identifying the underlying circumstances.

Dosage and Administration

Current FDA prescribing information recommends 100 mg once daily at bedtime for the approved product. Taking flibanserin at bedtime is intended to reduce risks associated with hypotension, fainting, accidental injury, and central nervous system depression that may occur when the medicine is taken during waking hours.

The requested ZPHC presentation is labeled as 50 mg tablets, which differs from the FDA-approved 100 mg tablet strength. Patients should therefore not change, combine, split, or otherwise modify doses based solely on an online product description. A licensed healthcare professional should determine the appropriate formulation and dose.

FDA labeling also states that treatment should be discontinued after eight weeks if there is no improvement.

Important Safety Information

Flibanserin has significant safety considerations. The FDA-approved labeling carries a boxed warning concerning hypotension and syncope in certain settings. These risks make it especially important to understand medication interactions and alcohol restrictions before treatment.

Alcohol Interaction

Alcohol can increase the risk of severe low blood pressure and fainting when taken close in time to flibanserin. The current FDA labeling provides specific instructions concerning alcohol consumption and bedtime dosing. Patients should carefully follow their prescriber’s instructions and the current medication guide rather than relying on generalized online advice.

CYP3A4 Interactions

Flibanserin is contraindicated with moderate or strong CYP3A4 inhibitors because these medicines can increase flibanserin concentrations and consequently increase the risk of hypotension and syncope. Medication interactions should therefore be reviewed with a healthcare professional before treatment.

Liver Impairment

Flibanserin is also contraindicated in patients with hepatic impairment because impaired liver function can substantially increase flibanserin exposure and raise the risk of serious adverse effects.

Central Nervous System Effects

Flibanserin can cause central nervous system depression, including sleepiness and sedation. The FDA advises patients to avoid activities requiring full alertness until they understand how the medication affects them.

Potential Adverse Reactions

According to current FDA prescribing information, commonly reported adverse reactions include dizziness, somnolence, nausea, fatigue, insomnia, urinary tract infection, anxiety, sinusitis, constipation, and dry mouth.

This information highlights an important point for anyone researching Flibanserin ZPHC: a prescription medicine should not be evaluated solely according to marketing language or perceived benefits. Understanding potential adverse effects is an essential part of making an informed healthcare decision.

Flibanserin and Sexual Health

Sexual desire is influenced by numerous biological, psychological, medication-related, and relationship factors. FDA-approved flibanserin treatment is therefore limited to a defined medical diagnosis rather than being intended as a universal solution for low libido.

The FDA specifically states that flibanserin is not indicated in men and is not indicated to enhance sexual performance. The current labeling applies to women younger than 65 years who meet the specified criteria for acquired, generalized HSDD.

This distinction can help consumers identify misleading product claims and better understand what flibanserin is actually approved to treat.

Why Accurate Product Information Matters

When researching a product such as Flibanserin ZPHC 50 mg × 100 tablets, accurate labeling information is particularly important. Prescription medications can have clinically significant interactions, contraindications, and dosing requirements that cannot be determined from product packaging alone.

The FDA has also warned consumers about sexual-enhancement products containing undeclared flibanserin and other pharmaceutical ingredients. In April 2026, the agency reported that a product marketed as a sexual-enhancement supplement contained flibanserin, sildenafil, and tadalafil that were not declared on its label.

For this reason, consumers should be cautious about products marketed with broad sexual-enhancement claims or products whose ingredients, strength, manufacturing source, or regulatory status are unclear.

Researching ZPHC Flibanserin in the USA

Searches for ZPHC, ZPHC Flibanserin, Flibanserin 50 mg, Flibanserin 100 tablets, and related terms can return products from different sources. Consumers should distinguish between a product’s commercial description and the FDA-approved labeling for the active pharmaceutical ingredient.

For U.S. treatment decisions, the FDA-approved prescribing information remains an important reference for understanding the labeled indication, dosage, contraindications, warnings, adverse reactions, and drug interactions.

A healthcare professional can also determine whether low sexual desire meets the diagnostic criteria for HSDD and whether other conditions or medications could be contributing to symptoms.

Frequently Asked Questions

What is Flibanserin?

Flibanserin is a prescription medicine used under FDA labeling to treat acquired, generalized HSDD in women younger than 65 years who meet the specified diagnostic criteria.

Is 50 mg the FDA-approved tablet strength?

The current FDA prescribing information identifies 100 mg as the approved tablet strength. A product labeled as 50 mg should therefore be evaluated carefully rather than assumed to be equivalent to the approved U.S. presentation.

Is flibanserin a sexual-performance enhancer?

No. FDA labeling specifically states that flibanserin is not indicated to enhance sexual performance.

Can flibanserin be taken with alcohol?

Alcohol can increase the risk of severe hypotension and syncope. Patients should follow the current FDA labeling and individualized instructions from their healthcare professional concerning alcohol and dosing.

Does flibanserin interact with other medicines?

Yes. Particularly important interactions include moderate or strong CYP3A4 inhibitors, while other medicines can also affect flibanserin exposure or adverse-effect risk. A complete medication review is recommended.

Final Considerations

Flibanserin ZPHC — 50 mg × 100 tablets is a product presentation that requires careful evaluation because the listed 50 mg strength differs from the 100 mg tablet strength identified in current FDA-approved labeling for flibanserin. Rather than relying on promotional claims, consumers should verify the product’s labeling, formulation, source, and regulatory status and discuss treatment with a qualified healthcare professional.

The most important takeaway is that flibanserin has a specific FDA-approved indication and significant safety considerations. Understanding these details can help consumers make informed decisions and avoid potentially dangerous medication interactions or inappropriate use.